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Abstract
DNA mismatch repair suppresses gastrointestinal tumorgenesis. Four mammalian E. coli MutL homologues heterodimerize
to form three distinct complexes: MLH1/PMS2, MLH1/MLH3, and MLH1/PMS1. To understand the mechanistic contributions
of MLH3 and PMS2 in gastrointestinal tumor suppression, we generated Mlh3
2/2;Apc
1638N and Mlh3
2/2;Pms2
2/2;Apc
1638N
(MPA) mice. Mlh3 nullizygosity significantly increased Apc frameshift mutations and tumor multiplicity. Combined
Mlh3;Pms2 nullizygosity further increased Apc base-substitution mutations. The spectrum of MPA tumor mutations was
distinct from that observed in Mlh1
2/2;Apc
1638N mice, implicating the first potential role for MLH1/PMS1 in tumor
suppression. Because Mlh3;Pms2 deficiency also increased gastrointestinal tumor progression, we used array-CGH to identify
a recurrent tumor amplicon. This amplicon contained a previously uncharacterized Transducin enhancer of Split (Tle) family
gene, Tle6-like. Expression of Tle6-like, or the similar human TLE6D splice isoform in colon cancer cells increased cell
proliferation, colony-formation, cell migration, and xenograft tumorgenicity. Tle6-like;TLE6D directly interact with the
gastrointestinal tumor suppressor RUNX3 and antagonize RUNX3 target transactivation. TLE6D is recurrently overexpressed
in human colorectal cancers and TLE6D expression correlates with RUNX3 expression. Collectively, these findings provide
important insights into the molecular mechanisms of individual MutL homologue tumor suppression and demonstrate an
association between TLE mediated antagonism of RUNX3 and accelerated human colorectal cancer progression.
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Introduction
Colorectal cancer (CRC) is one of the common malignancies in
industrialized countries. Lynch syndrome, a highly penetrant
disorder that confers predisposition to cancer of the colorectum,
endometrium and other extra-colonic sites [1], is caused by
germline mutations in DNA Mismatch Repair genes (MMR).
Including sporadic forms, defective MMR underlies ,12–15% of
CRC [2]. MMR plays critical roles in the maintenance of
genomic stability in both prokaryotes and eukaryotes [3]. The
study of model organisms has yielded great insights into the
mechanisms through which MMR prevents cancer
[1,3,4,5,6,7,8]. Briefly, there are nine mammalian MMR genes
(MLH1, MLH3, PMS1-2, MSH2-6). The mammalian E coli MutS
homologues (MSH) directly contact DNA, scanning along the
genomic DNA for mismatches analogous to a ‘‘sliding clamp’’
until they encounter a base-pair containing a mismatch [9,10].
MSH2-MSH6 primarily recognizes single-base substitutions and
1 base-pair insertion-deletion loop (IDL) mutations, while MSH2-
MSH3 recognizes 1–4 base-pair insertion-deletion mutations
[1,3].The IDL repair deficiency is commonly referred to as
Microsatellite Instability (MSI). The MSH proteins interact with
multiple proteins including the mammalian E coli MutL
homologues (MLH) and yeast post-meiotic segregation (PMS)
homologue proteins (which have significant amino acid identify
and structural similarity to the MLH proteins), as well as RPA,
EXO1, RFC, HMGB1, POLDC and other proteins [1,8,11,12].
MLH1-PMS2 is the primary MutL complex that interacts with
both MSH2/6 and MSH3 complexes. MLH1–MLH3 is less well
characterized, but is believed to participate in IDL repair [13,14],
DNA damage response [13], and possibly single-base point
mutation repair (SBR)[15]. MLH1-PMS1 exists in mammalian
cells but currently has no clearly defined roles in processes related
to cancer prevention [16,17].
PLoS Genetics | www.plosgenetics.org 1 June 2008 | Volume 4 | Issue 6 | e1000092To study the precise mechanisms through which MMR
suppresses carcinogenesis in vivo, we and others
[16,18,19,20,21,22,23,24] previously developed several mouse
models carrying mutations in different MMR genes. Mlh1
2/2
and Msh2
2/2 mice develop early onset GI epithelial cancers,
lymphomas and other types of cancer. Pms2
2/2 mice develop
lymphomas, but not GI epithelial cancers. Mlh3
2/2 mice develop
GI and extra-GI tumors, have decreased survival when compared
with Wt mice, but with later onset than Mlh1
2/2 [13]. Mlh3
2/
2;Pms2
2/2 mice have increased cancer incidence, resistance to
apoptosis and MSI [13]. However, the precise mechanisms in
which Mlh3 and Pms2 participate to suppress GI epithelial
tumorigenesis and progression remain poorly characterized.
Germ-line mutations in tumor suppressor gene APC lead to
familial adenomatous polyposis (FAP) [25,26]. Mutations in APC
are found in the majority of sporadic CRC and many Lynch
syndrome tumors [27,28]. APC complexes with AXIN and CK1/2
and destabilizes b-Catenin by enhancing proteasomal destruction.
Mutated APC proteins are unable to down-regulate b-Catenin, and
thestabilized b-Catenintranslocatesintothenucleuswhereitactsas
a transcriptional coactivator of the DNA binding protein TCF-4
[29,30]. More than 95% of APC germ-line mutations are truncating
or nonsense mutations and most of the pathogenic mutations are
located within the first 1500 codons. Apc mutations cooperate with
MMR deficiency in both tumorigenesis and tumor progression.
Apc
1638N mice are a well characterized model that develops GI
cancer [31]. Mlh1
2/2;Apc
1638N mice showed significantly increased
GI tumor multiplicity and accelerated progression to adenocarci-
noma compared to either mutation separately. Analyses of GI
tumors from Mlh1
2/2;Apc
1638N and Msh3
2/2;Msh6
2/2;Apc
1638N
mice revealed that both single-base substitutions and MSI induced
frameshift mutations in repetitive sequences were responsible for
most mutations found in the remaining wild-type (Wt) Apc allele
[32,33]. In contrast, tumor-associated Apc mutations found in the
Wt Apc allele in Msh6
2/2;Apc
1638N tumors were predominantly
single-base point mutations.
To understand more precisely the mechanistic roles that Mlh3
and Pms2 play in GI tumor suppression, we generated Mlh3
2/
2;Apc
1638N (MA) and Mlh3
2/2;Pms2
2/2;Apc
1638N (MPA) mice. We
show that in vivo Mlh3 mutations significantly increase frameshift
mutation rates in Apc, and increase GI tumorigenesis. Unlike
typical MSI-induced mutations, Mlh3 deficiency also results in
frameshift mutations in non-repetitive sequences, a unique
mutational signature among MMR deficient mice found only in
Mlh3 deficient mice. Consistent with the role of Pms2 in SBR,
combined Mlh3 and Pms2 mutations proportionally increase point
mutations and show a sequence preference for a CpG mutation
hotspot also previously seen in Mlh1
2/2 mice. Because MPA
mutant mice also have significantly increased rates of GI
adenocarcinomas vs. Apc
1638N or MA mice, we investigated
mechanisms of tumor progression. Using array-CGH, we
identified a recurrent 5-Mb amplification on chromosome 12 in
GI tumors from MPA mice. We defined the amplicon critical
interval and demonstrated that it contains a previously unchar-
acterized member of the Transducin enhancer of Split (TLE)/Groucho
family of transcriptional co-regulators, Tle6-like, that contributes to
tumor progression. Tle6-like overexpression in colon cancer cell
lines increases cell proliferation, colony-formation ability, cell
migration and xenograft tumorigenicity. Human TLE6D,a n
alternatively spliced isoform of TLE6, with a domain structure
similar to Tle6-like, has functional activity similar to Tle6-like. Both
Tle6-like and TLE6D interact with GI tumor suppressor, RUNX3
[34], and antagonize RUNX3 gene target tranactivation. TLE6D is
overexpressed in multiple human microsatellite stable (MSS) and
microsatellite unstable (MSI-H) CRCs, and TLE6D expression
levels correlate with RUNX3 expression levels. Collectively, these
findings provide important insights into the molecular mechanisms
through which MMR-deficiency contributes to GI tumorigenesis
and implicate a novel association between TLE6 isoforms and
antagonism of RUNX target gene expression in CRC tumor
progression.
Results
Mlh3, Pms2 and Apc Mutations Cooperate to Increase
Tumor Incidence, Accelerate Progression and Decrease
Overall Survival
By 9.5 months of age, MA mice develop .50% more tumors
than Apc
1638N mice (P,0.001; Mann-Whitney) (Figure 1A and C).
However, the relative ratios of GI adenomas to carcinomas in
Apc
1638N mice (65% and 35% respectively) were very similar to
that seen in MA mice (70% and 30% respectively) and overall
survival is not significantly affected (9.5 vs. 10.5 months). No
significant effect was seen on extra-GI cancer incidence or
progression. These data suggest the primary role of Mlh3 is in
suppression of GI tumor initiation and not tumor progression.
To study the effects of combined Mlh3 and Pms2 mutations in
vivo, we generated MPA mice. MPA mice had significantly shorter
survival vs. Apc
1638N or MA mice (P,0.01, Mann-Whitney test;
Figure 1A, C) and developed significantly more adenocarcinomas
than MA or Apc
1638N mice (Figure 1B, C) (P=0.022 MPA vs. MA
and p=0.0003 MPA vs. Apc
1638N). These are consistent with a role
for Mlh3;Pms2 combined loss both to increase GI tumor initiation
and accelerates progression. However, mean overall survival of
MPA mice is longer than that previously seen in Mlh1
2/2;Apc
1638N
mice [35].
Spectrum of Apc Mutations in MA and MPA Mice Tumors
In vitro studies have alternatively suggested that Mlh3 partici-
pates in either IDL repair [13] or SBR [15]. To understand the
role of Mlh3 in these processes, we used the wild type Apc allele as a
tumor-associated in vivo reporter gene to analyze the mutation
spectrum from MA GI tumors. A total of 49 tumors from MA mice
and 28 tumors from Apc
1638N littermates were analyzed for Apc
Author Summary
Approximately one million people every year are diag-
nosed with colorectal cancer worldwide, and about five
hundred thousand of these people subsequently perish
from the disease. Colorectal cancer is thought to develop
through a series of early and later stages (called cancer
initiation and progression, respectively). Deaths from
colorectal cancer are particularly tragic because the
disease can usually be cured if discovered before full-
blown progression. However, our knowledge of how these
tumors progress remains very limited. DNA mismatch
repair is known to be an important process in preventing
,15% of colorectal cancer initiation. In this study we
describe how two of these genes (Mlh3 and Pms2) that
have partial functional redundancy and therefore individ-
ually are rarely mutated are also important in preventing
colorectal cancer progression. Additionally, we describe a
new gene (Tle6-like) that, when overactive, makes these
cancers progress more rapidly. The overall goal of this
study is to understand colorectal cancer progression better
so that we can come up with new ways to block it at the
later stage.
Mechanisms of MMR Suppress GI Tumorigenesis
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were detected in 27 of 49 (55%) MA tumors while only 9 of 28
(32%) were found in Apc
1638N tumors. The current observed
incidence of Apc somatic mutations of Apc
1638N tumors is in
agreement with the previous results (7 of 22, 32%) [36], hence for
better understanding of mutational differences between the two
strains, this and the previous data for Apc
1638N tumors were
combined and used for further comparisons. This 23% increase in
somatic Apc mutations in MA mice was significant (P,0.0048;
Fisher exact test) and was attributable to increased small insertion/
deletion frameshift mutations (62.5%) vs. Apc
1638N (33.3%) mice
(P,0.001; Fisher exact test; Figure 2B and Tables 1 and 2). MA
Figure 1. Decreased survival and increased tumor multiplicity and progression in MPA mice. (A) Kaplan-Meier survival analysis of mice
deficient in Apc and DNA Mismatch Repair genes. (B, left) Three small intestinal adenomatous polyps from MPA mouse duodena are seen in cross-
section (arrows, left panel). (B, right panel) Example of a jejeunal adenocarcinoma from an MPA mouse, showing atypical glands (arrows) invading
deeply into a desmoplastic stroma (asterisks) containing a mixed chronic inflammatory reaction (arrowheads). (C) Tumor incidence and multiplicity.
a
Data from Chen et al[13].
b Data from Edelmann et al [35], for comparison. NA, data not available.
doi:10.1371/journal.pgen.1000092.g001
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observed in Mlh1;Apc
1638N mice (amino acid 1464) (Figure 2A).
Furthermore, examination of the sequences surrounding each Apc
mutation site in MA tumors showed that, unlike in other mismatch
repair deficient tumors such as Mlh1
2/2;Apc
1638N or Msh6
2/2;
Msh3
2/2;Apc
1638N [32,33], about 40% of frameshift mutations
occurred at non-repetitive sequences within the Apc coding region.
These data are consistent with a primary in vivo role for Mlh3 in
DNA repair of small insertion/deletion mutations in GI epithelial
cells.
We also studied the tumor-associated Apc mutations in GI
tumors from MPA mice. The overall incidence of Apc truncation
mutations in MPA tumors were similar to that observed in MA
tumors, yet the nature of mutations characterized was distinct.
Compared with MA mice (37.5%), combined Mlh3;Pms2 deficien-
cy caused a significant increase in the proportion of single-base
point mutations (57.2%, P,0.01; Figure 2 and Table 2). Within
the types of single-base point mutations, MPA tumors showed
higher frequency of C:GRT:A transition mutations (12 of 16,
75%) compared to MA tumors (7 of 12, 58.3%). However, this
Figure 2. Distribution of Apc mutations. (A) Diagram of Apc between codons 677 and 1674 showing positions and characteristics of truncation
mutations detected in MPA (top), MA (middle) and Apc
1638N (bottom) gastrointestinal tumors. (Open triangle symbol, deletion; solid triangle, insertion;
blue bar, substitution). Each symbol represents an independent mutation. Note the common hotspots at position 1464 in both strains. The three 15-
aa (A–C), four 20-aa (1–4) b-catenin binding repeats and one SAMP repeat in this segment of Apc are indicated. The two nuclear export signals are at
the ends of the third and fourth 20-aa repeats. (B) Spectrum of Apc truncation mutations in MMR deficient Apc
1638N tumors.
a Combined with
previous data from Wong et al, 2002.
b Data from Kuraguchi et al, 2000, for comparison.
doi:10.1371/journal.pgen.1000092.g002
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1638N
tumors which showed the majority (23 of 25, 92%) of base
substitutions to be transition mutations[32]. The C:GRT:A
transition mutations found in tumors, irrespective of genotypes,
occurred at either CpG dinucleotides or CpNpG sites, typical
targets for DNA methylation. Among these, Apc codon R854
seems to be a preferential target for base substitution mutation,
which was not only demonstrated to be a mutational hotspot in
Mlh1;Apc
1638N mice [32] but also in MPA mice.
Identification of Genomic Copy Amplification in MPA
Tumors Associated with Tumor Progression
Apc mutation is thought to be an early event in CRC
carcinogenesis. The significantly increased number of adenocar-
cinomas vs. adenomas seen in MPA vs. MA or Apc
1638N mice
suggested that MPA tumors have accelerated tumor progression.
While there is extensive evidence that increased mutation rates
and decreased apoptosis contribute to MMR defective CRC, it is
likely that additional mechanisms participate in tumor progression
as well. Because chromosomal and segmental aneuploidy has been
described in a subset of MMR deficient adenocarcinomas
[37,38,39], we performed array comparative genomic hybridiza-
tion (aCGH) analyses of GI tumor vs. E18.5 C57BL/6 embryonic
control DNA from Apc, MA, and MPA mice to identify specific
genetic changes that accelerate MPA GI tumor progression.
Comparison of aCGH profiles revealed a recurrent 5-Mb base
pairs amplification on chromosome 12F2 (66.7%,83.3%; see
Table 3 for detail; Figure 3A and B) in MPA GI tumors not seen in
Apc
1638N or MA tumors (Figure S1). To define the critical interval
for this amplification on chromosome 12F2 we bred a new cohort
of MPA mice and quantified copy number variation in the tumor
using real-time quantitative PCR (qPCR) (Figure 3C and Table 4).
Using qPCR with primer sets for the six genes within the amplified
region and two flanking genes, we identified one gene that showed
recurrent increased level of genomic DNA in tumor tissues
(Figure 3C), Transducin-like enhancer protein 6-like, (Tle6-like). TLE
family members act as transcriptional corepressors [40,41] without
any intrinsic DNA-binding activity. They are recruited to specific
gene regulatory sequences in a context-dependent manner by
forming complexes with different DNA-binding transcription
factors. Two evolutionarily conserved domains define the TLE
gene family: an N-terminal glutamine-rich (Q) domain that
mediates TLE family member heterodimerization, and a C-
terminal domain of WD motif repeats that mediates direct
interactions with sequence specific DNA binding transcription
factors (Figure 4)[40,41]. Previously TLE family members have
been described containing only the Q domain, such as Grg1-S [42],
or only the WD repeat motif, such as Grg6/Tle6[43]. Tle6-like
similarly contains only the C-terminal WD repeat domain and had
highest amino acid identity (84.4%) with TLE6 (Figure 4A and
Figure S2).
RNA and Protein Expression Levels of Tle6-like Are
Increased in MPA Tumors
To understand the impact of gene amplification on Tle6-like
expression, we isolated total RNA from tumor and normal tissues
from MPA mice and used qPCR to quantify relative Tle6-like
mRNA expression. As a result of copy number amplification, Tle6-
like mRNA levels were significantly increased in tumors compared
with adjacent normal GI tissue (Figure 3D). To understand
whether Tle6-like protein levels are subsequently increased, we
generated anti-Tle6-like specific antisera. Western blot analysis
with this antisera demonstrated that Tle6-like protein levels are
significantly increased in GI tumors compared to surrounding
normal GI epithelial tissue from MPA mice (Figure 3E). Overall,
these data suggest increased genomic DNA copy number of Tle6-
like causes increased mRNA and protein expression of Tle6-like in
MPA tumors.
Expression Level of TLE6 Alternative Spliced Isoform D
(TLE6D) Is Increased in Human Colorectal Tumors
Gene diversity can be generated by several mechanisms,
including gene duplication and paralogue evolutionary divergence,
and the generation of alternative mRNA splice isoforms that
modify coding sequence. The mouse Tle6-like-containing amplicon
is syntenic to human chromosome 14q33, but amplification of this
chromosomal region is not associated with CRC. Upon further
analysis, we discovered that 14q33 contains no human ortholog of
mouse Tle6-like, or any other TLE family member. However, when
we analyzed TLE6 mRNAs bioinformatically, we identified a
previously identified alternative spliced isoform of TLE6 (TLE6D)
(Genbank Accession #BX375733) that contains only the C-
terminal WD repeat domain of TLE6, and therefore has the same
domain structure as mouse Tle6-like (Figure 4B) To understand
expression of TLE6A (full-length isoform) and TLE6D in human
CRC, we generated three sets of RT-PCR primers: one for the
TLE6D N-terminus, one crossing the splice junction that is specific
for TLE6D and one that detects TLE6A but not TLE6D
(Figure 4B). We then calculated expression of these transcripts in
40 human CRC samples and normal tissue. Compared to adjacent
normal tissue, the TLE6D-specific and TLE6 C-terminus qPCR
showed significantly increased expression in a subset of human
CRCs (Figure 5A), but not for the TLE6 N-terminal or TLE6A
qPCR (data not shown). These data suggest that the TLE6D
isoform specifically is overexpressed in a subset of human
CRCs.
Table 1. Apc truncation mutations in intestinal tumors from MutL homolog deficient Apc
1638N mice.
+/+ Apc
1638N a Mlh3
2/2 Apc
1638N Mlh3
2/2 Pms2
2/2 Apc
1638N Mlh1
2/2 Apc
1638N b
Tumor DNA samples analyzed 50 (100%) 49 (100%) 49 (100%) 44 (100%)
Tumors samples with Apc truncations detected by IVTT 16 (32%) 27 (55%) 25 (51%) 37 (84%)
Tumor samples showing .1 mutant allele 2 (4%) 5 (10%) 4 (8.1%) 29 (66%)
Total Apc mutations characterized by sequencing 18 (100%) 32 (100%) 28 (93%) 91 (100%)
aCombined with previous data from Wong et al 2002 [36].
bData from Kuraguchi et al 2000 [32] for comparison.
doi:10.1371/journal.pgen.1000092.t001
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1638N tumors.
Codon Mutation Conseq- uence Wild-type Sequence
b Apc
1638N Mlh3
2/2 Apc
1638N
Mlh3 Pms2
2/2
Apc
1638N
769 GRTG l u RStop TTA TCA GAA ACC TTC - 1 -
778 DT frameshift AAC CTA AGT CCC AAG - - -
803 CRTA r g RStop GCC AAT CGA CAT GAT - 2 -
808 DG frameshift GAT AGT AGG TCA GAC 1 - -
819 DTG frameshift ATG ACTG TT CTT TCA - 1 -
847 DAC frameshift GAG AAA GAC AGA AGT - 1 -
848 DAG frameshift AAA GAC AGA AGT TTG - 1 -
853 DAG frameshift GAG AGA GAG CGA GGT - 1 -
854 CRTA r g RStop GAG AGA GAG CGA GGT - 1 4
866 GRTG l u RStop ACA ACA GAA AAT GCA - - 1
871 DTC frameshift GGA ACC TCA TCA AAA - 1 -
872 CRA SerRStop ACC TCA TCA AAA CGA - - -
874 CRTA r g RStop TCA AAA CGA GGT CTG 1
a -4
884 CRTG l n RStop GCA GCC CAG ATA GCC - - 1
902 DAG frameshift GAC GAC AGA AGT TCT - 1 -
909 GRTG l u RStop ACC ACC GAG TTC CAT - 1 -
913 DTG frameshift CAT TGT GTG GCA GAC - 1 -
921 CRTA r g RStop GCG GCA CGA AGA AGC 3
a 2-
933 CRAT y r RStop AAC ACA TAC AAC TTC 1 - -
934 +TACA frameshift AAC ACA TAC AAC TTC 1
a --
939 GRTG l u RStop AAG TCG GAA AAT TCA 2 - 1
944 D38bp frameshift TCAAATAGGACATGCTCTATGCCTTATGCCAAAGT-
GGAATATAAACGA TCT TCA AAT
1- -
956 CRTA r g RStop TAT AAA CGA TCT TCA 1 1 1
959 DA frameshift TCT TCAA AT GAC AGT - - 1
974 DAA frameshift GGT AAAA GA GGC CAA 1
974 DGA frameshift GGT AAA AGA GGC CAA 1
984 TRAT y r RStop GAA TCC TAT TCT GAA - 1 -
992 +T frameshift AAA TTT TGC AGT TAT - 2 -
992 D8bp+A frameshift AAA TTT TGC AGT TAT 1
a --
1004 DC frameshift GAC CTA GCC CAT AAG - 1 -
1018 GRTG l u RStop GAT GGA GAA CTG GAT 1 - -
1025 CRAT y r RStop ATA AAT TAC AGT CTT - 1 -
1025 DAC frameshift ATA AAT TAC AGT CTT 1 - 2
1047 GRAT r p RStop GAA AGG TGG GCA AGA 1
a 11
1127 +T frameshift CAG TCT CTG TGT CAG 1 - -
1127 DCT frameshift CAG TCT CTG TGT CAG 1
1128 DGT frameshift TCT CTGT GT CAG GAA - 1 -
1141 CRAT y r RStop ACC AAC TAC AGT GAA 1 - -
1143 GRTG l u RStop TAC AGT GAA CGT TAT 1 - -
1154 GRTG l u RStop GAA GAA GAA GAA GAG 1
1157 DGA frameshift GAA GAG AGA CCG ACA 1
1211 DTC frameshift CAT CTC TCTC CA AGC - 1 -
1219 DG frameshift ACA GCT GTA CCT CCA - 1 -
1227 CRTG l n RStop AAA AGG CAG AAT CAG - - 1
1272 CRAC y s RStop TCA AGG TGC AGT TCA - - 1
1234 CRA SerRStop CCA AGT TCA GCA CAA - 1 -
1244 DG frameshift CAA AAA GGC ACT ACT - 1 -
1370 DA frameshift ACA CCC AAA AGT CCC - 1 1
1464 DAG frameshift GAG AAG AGA GAG AGT- 5 4
Total 18 32 28
aPrevious data from Wong et al 2002.
doi:10.1371/journal.pgen.1000092.t002
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Formation, and Cell Migration
Because GI tumors from MPA mice showed increased number
of adenocarcinoma than Apc
1638N or MA mice, we evaluated
whether increased levels of Tle6-like can contribute to mechanisms
that underlie tumor progression. We generated stable cell 293 cell
lines that express Tle6-like or TLE6D. For both Tle6-like and
TLE6D overexpressing cell lines, cell proliferation rates were
significantly increased compared with vector-transfected control
cells (Figure 6A). Similar results were also seen in HCT116 and
3T3 cells (data not shown). We next tested the effect of Tle6-like/
TLE6 expression on the ability to form colonies in vitro. Mouse
embryonic fibroblasts transfected with Tle6-like or TLE6D
significantly increased colony formation (four-fold and two-fold,
respectively) compared with empty vector-transfected control cells
(Figure 6B and C). We also tested the mobility of the cells
transfected with Tle6-like/TLE6D by in vitro migration assay. Cell
lines stably expressing Tle6-like or TLE6D were able to migrate a
significantly longer distance when compared with control cell lines
expressing only the vector (Figure 6D). In contrast, no effect of
Tle6-like or TLE6D ectopic expression was seen on induction or
resistance of apoptosis induced by serum-depletion in culture
medium (data not shown). In summary, these results are consistent
with a proliferation and migration advantage for tumor cells
expressing Tle6sh or TLE6D.
Tle6-like and TLE6D Expression Increases Xenograft
Tumor Proliferation in vivo
Because Tle6-like or TLE6D ectopic expression increased cell
proliferation and migration in vitro, we evaluated their impact in
vivo. We injected HCT116 cells stably expressing Tle6-like, TLE6D
or vector s.c. into nude mice and quantified tumor growth. As
expected, HCT116 cells transfected with vector formed xenograft
tumors. In parallel, HCT116 cells expressing Tle6-like and TLE6D
formed significantly larger tumors (Figure 7). These results suggest
that Tle6-like and TLE6D expression increases CRC cell
proliferation and growth, in vivo.
Tle6-like and TLE6D Interact with the RUNX3 GI Tumor
Suppressor and Antagonize RUNX3 Mediated
Transactivation
RUNX genes encode transcription factors that activate or repress
transcription of key regulators of growth, survival and differenti-
ation pathways [44,45]. This gene family is defined by the Runt
domain, which mediates both protein-DNA and protein-protein
interactions with transcriptional co-regulators. TLE proteins
interact with, and regulate the function of, RUNX proteins through
direct interactions between the TLE WD domain and the Runt
domain and the interactions antagonize RUNX-mediated transac-
tivation [44,45,46,47,48]. RUNX3 has been shown to play
important roles in GI epithelial cell development and tumorgen-
esis. Loss of Runx3 predisposes knockout mice to gastric
hyperplasia, indicating a tumor suppressor-like role for this gene
[34,49,50,51,52]. In human gastric cancers, hypermethylation of
RUNX3, hemizygous deletion and truncating point mutations have
been observed [34,52,53,54,55,56,57,58]. To test whether Tle6-
like/TLE6D interact with RUNX3, we first evaluated sub-cellular
localization using immunofluorescence staining in 293 cells co-
transfected with Tle6-like or TLE6D and native RUNX3 (Figure
S3). Using anti-Myc, anti-Xpress and anti-RUNX3 antibodies, we
observed that highest levels of Tle6-like and TLE6 and are in the
nucleus overlapping with nuclear RUNX3 staining. Furthermore,
in 293 cells, transiently transfected with Tle6-like or TLE6D,
endogenous RUNX3 co-immunoprecipitated with anti-Myc or
anti-Xpress antibodies (Figure 8A and B), suggesting an interaction
between Tle6-like/TLE6D and RUNX3. Similar co-localization
and co-immunoprecipitation results were seen in HCT116 and
3T3 cells (data not shown). Finally, to evaluate the functional
consequences of Tle6-like/TLE6D interaction on RUNX3
transcriptional regulation we used a well characterized RUNX3
transactivation on promoter target, osteocalcin (OC), fused to a
luciferase reporter gene [47]. As expected, transfected RUNX3
activated luciferase expression in 293, Hela or HCT116 cells
(Figure 8C, lane 1 and 2). Co-transfection of Tle6-like or TLE6D
decreased RUNX3 transcriptional reporter activity in a dose-
dependent manner (Figure 8C), whereas Tle6-like/TLE6D trans-
fection had no effect on promoters lacking RUNX3 binding sites,
such as the TOPFLASH/FOPFLASH system (data not shown).
Taken together, these results are consistent with a model whereby
Tle6-like/TLE6D expression antagonizes RUNX3 GI tumor
suppressor mediated target gene transactivation through an
interaction between the Tle6-like/TLE6D and RUNX3, provid-
ing a selective growth advantage for cell proliferation and
migration.
TLE6D is Highly Expressed in Human CRCs with High
RUNX3 Expression Levels
In gastric cancer, RUNX3 activity is most commonly reduced
through a mechanism involving RUNX3 promoter hypermethyla-
tion and subsequently decreased mRNA expression. However, its
expression levels in CRC have not been well characterized. We
therefore used qPCR to evaluate RUNX3 expression in 40 human
CRC and matched normal GI epithelial samples, normalized to
GAPDH expression. In many CRCs, RUNX3 expression is low,
consistent with a role in GI tumor suppression. However, in a
subset of CRCs RUNX3 expression is paradoxically increased
(Figure 5B). To test whether elevated TLE6D expression is
associated with RUNX3 activation, we used qPCR to analyze
TLE6D expression levels in the same matched sets of CRCs and
normal mucosa. We observed a clear correlation of RUNX3 and
TLE6D expression levels (R=0.723; Figure 5C). However, at the
same time no clear correlation was seen for RUNX3 and TLE6D
expression levels with regard to MSI-H/MSS status or for
expression levels of the full length TLE6 and RUNX (data not
shown). Overall, in combination with the functional antagonism of
RUNX3 activity by TLE6D observed in colon cancer cells, the
correlation of RUNX3 and TLE6D expression in human CRCs
suggests that TLE6D may interact with the RUNX3 GI epithelial
tumor suppressor and inactivate RUNX3 in a subset of CRCs
independent of MSI status. However, further experiments will be
required to analyze the association between RUNX3 and TLE6D
expression levels and functional interactions in more detail.
Discussion
Because APC is a common mutation target in MMR-deficient
CRC, we created novel mouse models combining different
mutations in these genes to analyze their roles in MMR-deficient
GI carcinogenesis and progression. The observation that MA mice
have increased tumor multiplicity but no accelerated tumor
progression or decreased survival vs. Apc
1638N mice suggests a
primary role for the Mlh1–Mlh3 heterodimer in suppression of GI
tumor initiation. While previous in vitro studies have alternatively
suggested that Mlh1–Mlh3 participates in IDL repair [13] and
SBR[15,59], our study provides the first in vivo evidence that Mlh3
deficiency significantly increases IDL mutation frequency. This
type of mutation occurred both at repetitive and non-repetitive Apc
Mechanisms of MMR Suppress GI Tumorigenesis
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(Figure 2). Previous studies of Pms2
2/2;Apc
Min mice have shown a
primary role for Mlh1-Pms2 in GI tumorgenesis suppression but
not tumor progression[60]. We therefore combined these
mutations to create MPA mice. Like Mlh1
2/2;Apc
1638N mice,
MPA mice have significantly increased GI tumor multiplicity,
accelerated tumor progression and decreased overall survival[61] .
MPA tumors harbor proportionally more C:GRT:A (at either
CpG or CpNpG sites) transition mutations than MA tumors,
showing recurrence in certain arginine codons, one of which was
at Apc codon 854, a SBR hotspot that was also previously seen in
Mlh1
2/2;Apc
1638N mice.
In addition to Mlh1-Pms2 and Mlh1–Mlh3, several lines of
evidence from our study suggest a potential role for Mlh1-Pms1 in
suppression of GI tumorigenesis. First, MPA mice have later mean
GI tumor onset compared to previous studies of Mlh1
2/2;Apc
1638N
mice[32]. Second, the multiplicity of GI tumors is decreased vs
Mlh1
2/2;Apc
1638N mice. Third, two Apc insertion/deletion muta-
Figure 3. Array-CGH analysis of Mlh3;Pms2;Apc deficient GI tumors. (A) Display of CGH signal from a representative tumor genome wide. Red
arrow indicates the gain of signal on chromosome 12. (B) Higher resolution view of mouse chromosome 12 signal. Red dot line indicates the
amplification. (C) Quantitative PCR of genomic DNA level from MPA tumors. Dotted box indicates the amplified region detected by array-CGH. (D)
Quantitative PCR of Tle6-like level in cDNA from MPA tumors. (E) Immunoblot of Tle6-like in MPA tumors. N, normal tissues; T, tumors.
doi:10.1371/journal.pgen.1000092.g003
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2/2;Apc
1638N mice have not been
detected in MPA tumors. These data are consistent with previous
studies of yeast Mlh2p (orthologue of mammalian PMS1) that
demonstrate a minor role for this protein in IDL repair [62].
Because the combination of Mlh3, Pms2 and Apc mutations
accelerates tumor progression, we searched MPA GI tumor
specific genetic changes associated with progression using high-
resolution aCGH. MPA tumors contained a recurrent 5-Mb
amplicon with a critical interval containing a novel, poorly
characterized member of the TLE family of transcriptional co-
repressors, Tle6-like. Unexpectedly, this MPA recurrent amplifica-
tion hotspot is not detected by aCGH in GI tumors from Mlh1
2/2;
Apc
1638N mice (data not shown). The reason for this difference is
unclear, but again suggests that Mlh1-Pms1 may play a role in
causing chromosomal instability.
TLE genes are the mammalian homologues of Drosophlia groucho
that play critical roles in a wide range of developmental and
cellular pathways [40]. TLE proteins are transcriptional corepres-
sors for specific families of DNA-binding transcription factors,
including RUNX proteins[48]. In addition, Tle1/Grg1 has been
shown to act as a lung-specific oncogene in a transgenic mouse
model [63]. Mouse Tle6/Grg6 has been shown to synergize with
the E2A-HLF oncoprotein in antagonism of Runx1 transactivation
in murine pro-B cells, causing acute leukemogenesis [64]. Tle6/
Grg6 also participates in developmental mechanisms of neurogen-
esis [43]. Here, we provide data that a previously uncharacterized
TLE family member containing only the WD repeat domain,
Tle6-like, has amplified gene copy number, mRNA and protein
levels in GI epithelial tumors from MMR deficient/Apc mutant
mice, and is associated with accelerated tumor progression.
Consistent with this observation, in functional studies Tle6-like/
TLE6D enhances cell proliferation, colony-formation, migration
and xenograft tumorgenicity. While TLE family members have
previously been shown to repress Wnt/b-catenin signaling
[42,65,66,67], we were unable to demonstrate any Tle6-like/
TLE6D protein-protein interactions with b-catenin or effect of Tle6-
Figure 4. TLE Family. Schematic diagram of TLE protein family
members. (A) Numbers indicate amino acids. Q, glutamine rich domain;
GP, Glycine/praline rich domain; CcN, domain containing putative
phosphorylation sites and putative nuclear localization signal; SP,
serine/praline rich domain; WD repeats, domain containing series of
tandem repeats of tryptophan and aspartic acid residues. (B) Diagram of
TLE6 RNA and alternative splice form TLE6D is indicated. TLE6A is the full
length mRNA transcript. Orange bars indicate position of primer sets for
qPCR. Arrows indicate exon-exon junctions.
doi:10.1371/journal.pgen.1000092.g004
Table 3. Amplifications of Chromosome 12.
Chromosome Change Start Position Start Band End Position End Band Frequency
12 Gain 109,044,957 12 q F1 109,106,314 12 q F1 8 /12 (66.7%)
12 Gain 109,106,314 12 q F1 109,348,509 12 q F1 10/12 (83.3%)
12 Gain 109,348,509 12 q F1 109,556,449 12 q F1 9/12 (75%)
doi:10.1371/journal.pgen.1000092.t003
Table 4. Primers Used in Real-Time PCR.
Primer Sequences
Crip-F GGCTGCCACATTGAAAGAAT
Crip-F TCAGCTGCAGAAGCACAGAT
Cdc5L-F TGGCAATATATGCTGTCTTGTAGG
Cdc5L-F TGCCTCTTCCTCAAAGTCCT
Myef2l-F CATGGTCAGGCCTATCACAA
Myef2l-F GACTTCCCTTGGTCATGGTG
Tle6_F ACACTATCTTAGGCCTCAAGTTCTCTC
Tle6_R AGTCATGCCATAGCATCTGACAGT
Adam6-F CACCTGCATCATGTTCAAAAA
Adam6-R GACATGGCATCAGATCAGGA
Igh-a_F AGCAGTCTGAGGTCTGAGGACACGGCC
Igh-a_R2 TGCTCTTCAGGAGGTTTTAGTT
U110086690_F ATGGAATGGAGTTGGGTCTTT
U110086690_R TTTGTCATCGCAGACCCTGT
Vipr2_F GTGAGCAGCATCCATCCAG
Vipr2_R CCTCTCTGATTCTCCGTTTGG
Alkbh-F GTAATGCCTCCCAGAAGTGC
Alkbh-R CTGCTGAGCTGGTGAAATTG
doi:10.1371/journal.pgen.1000092.t004
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using TOPFlash in transient transfection in colon cancer cell lines
(data not shown), suggesting that Tle6-like/TLE6D might not be
involved in canonical Wnt pathway.
RUNX family genes regulate lineage and stage specific gene
transcription by direct binding to DNA promoters and
enhancer elements [44,45]. Loss of Runx3 in the mouse results
in the development of gastric mucosal hyperplasia, decreased
apoptosis and attenuated TGF-b anti-proliferative signaling.
Consistent with previous observations of interactions between
RUNX3 and TLE family members mediated through the Runt
and WD repeat domains, respectively [46,48], we detected an
interaction between RUNX3 and Tle6-like/TLE6D by co-
immunoprecipitation. Furthermore, we demonstrated that Tle6-
like/TLE6D antagonized RUNX3 regulated transcriptional
targets. However, while these experiments show an association
between RUNX3:TLE6D interactions and tumor progression,
they do not demonstrate mechanistically the functional
importance of this interaction in accelerating tumor progres-
sion.
Figure 5. TLE6D and RUNX3 mRNA expression levels in human colorectal cancers. (A,B) Dotplots of TLE6D and RUNX3 expression levels for
each of the 40 samples. Expression is shown as fold elevation vs. accompanying normal adjacent mucosa. (C) Superimposed plot of TLE6D and RUNX3
expression levels by sample (Pearson correlation 0.724; Pvalue,0.001). (D) A scatterplot of log-transformed RUNX3 by TLE6D expression levels along
with the least squares estimate of the regression of RUNX3 on TLE6D. Expression levels were log-transformed in the regression analysis due to heavy
skewness. Based upon the regression, it was estimated that the geometric mean of RUNX3 expression increased 0.525 with a 2-fold increase in TLE6D
expression (95% CI: 0.165, 0.563; p Value,0.001).
doi:10.1371/journal.pgen.1000092.g005
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produced from a single coding sequence, and through this
mechanism a higher diversity of mammalian genes is generated
[68]. Several distinct TLE/Grg gene alternative splice forms, such
as Grg-1s, QD of TLE4, and Grg3b [42,69,70], have been reported.
While the human genome does not encode a TLE6-LIKE ortholog,
a structurally equivalent protein, TLE6D, is generated through
alternative splicing. The observation that GI adenocarcinomas
from both humans and mice use two very distinct mechanisms to
amplify Tle6-like/TLE6D activity suggests a strong growth
advantage and selective pressure for this TLE isoform in tumor
progression. Similarly, the correlation between TLE6D and
Figure 6. Tle6-like and TLE6D Enhance Cell Proliferation, Colony Formation, and Cell Migration. (A) HCT116 Cell proliferation MTT assay.
(B) Representative picture of plates of colony formation assay on MEFs transfected with vector, TLE6D, and Tle6-like. (C) Plot of number of colonies
from colony formation assay. (D) In Vitro Cell Mobility Assay. ‘‘Wound’’ was generated by razor blade, clearing the adherent cells on the right side of
the slides. Black lines indicate the edge of the ‘‘wound’’. Representative pictures from HCT116 cells transfected with vector, TLE6D, and Tle6-like are
shown.
doi:10.1371/journal.pgen.1000092.g006
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RUNX3 inactivation by TLE6D could be an important factor
driving this growth advantage in both MSI-H and MSS CRC.
Future studies will be required to understand the mechanistic
implications of the interaction between these two proteins in CRC
progression in more precise detail.
Figure 7. Tle6-like and TLE6D Enhance Gastrointestinal Tumor Progression. (A) Left panel, Xenograft of HCT116 cell lines expression Tle6-
like or vector alone. Right Panel, Xenograft of HCT116 cell lines expression TLE6D or vector alone. (B) Representative xenograft tumors of HCT116 cells
expressing pCS2+MT -Tle6-like, pCS2+MT vector, pcDNA6/HisA-TLE6D and empty pcDNA6/HisA vector. (C) Tumor weight in HCT116 xenograft tumors
expressing Tle6-like or empty pCS2+MT vector and TLE6D and empty pcDNA6/HisA vector (Error bars indicate the standard deviation of the mean; p
Value,0.005).
doi:10.1371/journal.pgen.1000092.g007
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293 cells. Left panel represents the immunoblot of protein extracts before immunoprecipitation. Right panel represents the immunoblot after the
immunoprecipitation. (C) Luciferase reporter assay. Cells were transient tranfected with indicated plasmids and relative luciferase activities were
determined the next day. (Error bars indicate the standard deviation of the mean).
doi:10.1371/journal.pgen.1000092.g008
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Mouse Lines and Survival Analyses, Tumor Analysis, and
Apc Mutation Analysis
Wild-type (Wt), Pms2
+/2 and Mlh3
+/2 mice were maintained on
the 129 Sv/Ev genetic background and intercrossed to generate
Mlh3
+/2;Pms2
+/2 mice as described before [13]. Apc
1638N mice
were backcrossed four times to 129 Sv/Ev and subsequently
intercrossed with Mlh3
+/2; Pms2
+/2 to generate Mlh3
2/2;Apc
1638N
and Mlh3
2/2;Pms2
2/2;Apc
1638N mice. Kaplan-Meier survival
curves were generated and statistical significance between
genotypes was determined using the Log Rank test as previously
performed [13]. All lines of mice were necropsied when they
became morbid or moribund. Sacrificed mice were surveyed for
tumors and suspicious masses were histology analyzed as
previously performed. Statistical analyses of tumor onset and
incidence among the different mouse lines were performed using
the Mann-Whitney test as previously described
[23,32,33,35,71,72,73,74,75,76]. Tumors from stomach, small
intestine, and colon were cut into two parts. One part of the tumor
was processed for histopathological analysis and the other part was
used for DNA/RNA extractions. Genomic DNA samples were
extracted using Puregene DNA Isolation kit (Gentra Systems,
Minneapolis, MN) and subjected to mutational analysis of Apc
gene between codons 677–1674 as previously described [33].
Array Comparative Genomic Hybridization Analysis
Genomic DNAs were isolated from tumor tissue and tail tissue
from each mouse using PUREGENE DNA Isolation kit (Gentra
Systems, Minneapolis, MN). DNAs were digested with DpnII and
subsequently purified using the QIAquick PCR Purification kit
(Qiagen). The quality of the DNA samples was evaluated using the
Agilent 2100 BioAnalyzer. The purified fragmented DNA samples
were random-prime labeled with either Cy5 or Cy3 and
hybridized as previously described [77]
Briefly, for each labeling reaction, 2 mg of purified digested
DNA were used. Each sample was dye-swap labeled for
hybridization to mouse 70-mer oligonucleotide microarrays
(Agilent Technologies, Palo Alto, CA) containing 20,281 clones.
After hybridization, the arrays were scanned using an Agilent
Microarray DNA scanner (Agilent Technologies) and the spot
intensity was extracted from slide images using Agilent Feature
Extraction Software 7.0. The data were further analyzed using the
procedures of Automatic Data Analysis Pipeline (ADAP). Only
spots with fluorescence intensities statistically different from the
surrounding background (P,0.001) were considered reliable,
taking up .85% of total spots on the chip. For further analysis
the fluorescence intensity values of reliable spots were transformed
to log2. To minimize the effect of the variations, the log2 intensity
ratios of remaining spots were subjected to normalization by
Lowess fitting. Gene copy number changes for each sample was
calculated by taking the median of the normalized log2 intensity
ratios of dye-swapped chip experiments for the corresponding
sample. The gene copy numbers were ordered along chromo-
somes by the map positions of corresponding genes. To eliminate
systematic noise, gene copy number changes (log2Ratios) along the
chromosomes were smoothed by taking a moving median of
symmetric 5-nearest neighbors, followed by Lowess fitting (f=0.2).
The mean and standard deviation (SD) of smoothed log2Ratios for
all genes in all the samples were calculated. The copy number
profiles of at least 5 consecutive genes that deviated significantly
above mean+3SD were interpreted as regional gains, below mean-
3SD as regional losses. The threshold for whole chromosomal
gain/loss was mean62SD. The ideograms of chromosomal
aberrations were drawn using mapping information of cytogenetic
bands to the mouse genome (NCBI Mapview Build 32).
cDNA Preparation and Real-Time PCR
For RNA extractions, Trizol reagent (Invitrogen) was used to
isolate total RNA. RNA were further digested with RNAse-free
DNAseI (Promega) and cleaned with RNeasy Mini kit (Qiagen).
High Capacity cDNA Archive kit from Applied Biosystems was
used to make cDNA from the RNA samples. Real-time
quantitative PCR was performed with either SYBRGreen PCR
master mix or Taqman PCR master mix (Applied Biosystems)
following the manufacture’s protocol on ABI 7900 machine.
Primers used for SYBR Green assays are listed in Table 1. Each
gene was normalized to the internal control gene Gapdh and then
compared to a known single copy gene (Alkbh), which is located on
non-amplified region on chromosome 12 D3 in the MPA tumors.
Generation of Tle6-Like Antibody
The whole Tle6-like gene (encoded 240 amino acids) was cloned
in to pET28b vector and Tle-6like protein was induced and
purified from E. coli. Rabbit anti-serum was raised against Tle6-
like protein. The anti-serum was further purified using affinity
column, in which Tle6like protein was covalently bound to CNBr-
activated Sepharose 4B (Sigma). The purified antibody was used in
immunoblotting at 1:100 dilutions.
Cell Culture
HCT116, 293, Hela or 3T3 cells were maintained in DMEM
with 10%FBS and transfected using Lipofectamine 2000 (Invitro-
gen). The human isoform TLE6D cDNA clone was purchased
from Invitrogen (Full-length Human Clones CS0DC017YC05;
Accession number BX375733). Tle6-like was cloned from cDNA
samples from MPA mice. We subcloned Tle6-like and TLE6D into
either Xpress-epitope-tagged pcDNA6/HisA vector (Invitrogen)
or Myc-tagged pCS2+MT vector. Cells were transfected with
following plasmids: pcDNA6/HisA, pcDNA6/HisA-Tle6-like,
pcDNA6/HisA-TLE6D, pCS2+MT, pCS2+MT-Tle6-like,
pCS2+MT-TLE6D. Stable cell lines from each transfectant were
generated with the selection medium containing 10 mg/ml
blasticidin (Calbiochem) for 10 days. The pooled populations of
cells that survived were used in the experiments for MTT assay
and cell mobility assay. The transient-transfected cells were used
for colony formation assay, immunoprecipitation, and reporter
assay.
MTT Cell Proliferation Assay and Colony Formation Assay
For the cell proliferation assay, 4000 cells were plated in 96-well
plates and MTT assay were used to determine the cell numbers in
a time-course experiment. Briefly, cells were washed with PBS and
treated with 5 mg/ml MTT ([3-(4,5-dimethylthiazol-2-yl)- diphe-
nyltetrazolium bromide]Sigma, St. Louis, MO) for 5 hours. After
removal of MTT, DMSO was added to dissolve the dark purple
formazam crystals in the viable cells and absorbance of 600 nm
were determined by a multiwell scanning spectrophotometer. The
cell numbers were calculated with a control standard curve. For
colony-formation assay, MEF cells were seeded in 6 well plates and
transient-transfected with 1 mg of the respective plasmids in the
next day. After 24 h, cells were trypsinzed, transferred to 10-cm
plates and allowed to grow with the selection medium containing
10 mg/ml blasticidin for 2 weeks. Survived cells were fixed in 30%
ethanol and stained with 0.25% methylene blue. Colonies
containing more than 50 cells were counted. Both assays were
repeated three times in three independently-derived cell lines.
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The monolayer ‘‘wounding assay’’ was used to demonstrate the
in vitro cell migration. Human colon cancer HCT116 cells stably
expressing corresponding plasmids were plated on glass micros-
copy slides and cultured to confluence. A ‘‘wound’’ was generated
by scratching the slide with a razor blade, clearing a portion of
adherent cells on the slide. Photo documentation was taken at day
4 and the migration of cells from the cut edge of the monolayer
into the clear portion of the slides was assessed. Two indepen-
dently-derived stable cell lines for each plasmid were used in this
assay.
Antibodies, Immunoprecipitation, and Immunoblotting
Transient-transfected 293 cells in 10-cm plate were lysed with
1 ml of NP-40 lysis buffer and prepared as described before [13].
Five hundred ml of lysates were pre-cleared with 50 ml ProteinA/G
agarose beads (Santa Cruz) for 1 h. After spinning down the
ProteinA/G beads, the collected supernatants were incubated with
5 mg anti-Xpress or anti-myc monoclonal antibody (Invitrogen)
and 50 ml ProteinA/G beads overnight at 4uC. The next day, the
beads were washed with NP-40 buffer 5 times and incubate with
46 protein loading dye (Invitrogen) 10 min at 95uC to elute the
binding proteins. These samples were resolved by SDS-PAGE and
the immunoblotting was used as previously described to detect the
corresponding proteins. The antibodies used in immunoblotting
are: mouse monoclonal anti-Xpress and anti-myc (1:2000,
Invitrogen), rabbit anti-RUNX3 (1:1000, Abcam) and goat anti-
b-actin (1:1000, Santa Cruz Biotechnologe).
Luciferase Reporter Assay
293, Hela or 3T3 cells were transient-transfected accordingly
with the Flag-RUNX3 (a kind gift from Dr. Yoshiaki Ito) and rat
Osteocalcin promoter fused to luciferase reporter construct (OC-
Luci, a kind gift from Dr. Gary Stein), and plasmids as described
above. Luciferase activities were determined using Dual-Luciferase
reporter assay systems kit (Promega) on the luminemeter.
Tumor Growth in Nude Mice
Female 6-week-old nude mice (Charles River Laboratories,
Wilmington, MA) were divided into four experimental groups, five
for each. One million HCT116 cells stably transfected with vectors
(pCS2+MT or pCDNA6/HisA), pCS2+MT-Tle6sh,o rpCDNA6/
HisA-TLE6D were injected subcutaneously in the flanks of each
mice. Mice were monitored daily for palpable tumors. Because of
rapid growth, tumors were dissected out 3 weeks after injection
and were analyzed.
Supporting Information
Figures S1 Array Comparative Genome Hybridization (aCGH)
analysis of GI tumors. (A) Display of aCGH signal genome wide
from a representative Apc1638N tumor. (B) Display of aCGH
signal genome wide from a representative Mlh32/2;Apc1638N
tumor. (C) Display of aCGH signal genome wide from a
representative Mlh32/2;Pms22/2 tumor.
Found at: doi:10.1371/journal.pgen.1000092.s001 (0.07 MB PPT)
Figure S2 Protein sequences of TLE family.
Found at: doi:10.1371/journal.pgen.1000092.s002 (1.95 MB
PNG)
Figure S3 Cellular localization of endogenous RUNX3 and
transfected Myc-epitope tagged Tle6-like in 293cells. Mouse
monoclonal anti-myc and rabbit anti-RUNX3 were used.
Secondary FITC-conjugated anti-mouse and Cy5-conjuaged
anti-rabbit antibodies were used respectively. DAPI (49,6-diami-
dino-2-phenylindole) staining indicates the nuclear location.
Found at: doi:10.1371/journal.pgen.1000092.s003 (0.19 MB PPT)
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